Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN  
650.25
-2.93 (-0.45%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)69.41B
Current PE11.19
Forward PE 11.26
2yr Forward PE 14.49
See more stats
Estimates Current Quarter
Revenue$2.74 Billion
Adjusted EPS$9.73
See more estimates
10-Day MA$654.22
50-Day MA$623.49
200-Day MA$530.00
See more pivots

Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 9123

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.